Repligen Co. (NASDAQ:RGEN) shares fell 4.2% on Monday . The stock traded as low as $308.67 and last traded at $309.71. 1,289 shares changed hands during mid-day trading, a decline of 100% from the average session volume of 384,809 shares. The stock had previously closed at $323.26.
Several brokerages recently weighed in on RGEN. KeyCorp lifted their price objective on Repligen from $255.00 to $335.00 and gave the stock an “overweight” rating in a report on Friday, September 17th. Stephens lifted their target price on Repligen from $255.00 to $290.00 and gave the company an “overweight” rating in a report on Friday, August 20th. Finally, Craig Hallum lifted their target price on Repligen from $258.00 to $368.00 and gave the company a “buy” rating in a report on Monday. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Repligen has a consensus rating of “Buy” and an average target price of $280.50.
The company has a market cap of $16.60 billion, a PE ratio of 169.32 and a beta of 0.90. The company has a fifty day moving average price of $266.43 and a 200 day moving average price of $220.21.
In other Repligen news, Director Karen A. Dawes sold 4,585 shares of the business’s stock in a transaction that occurred on Tuesday, July 20th. The stock was sold at an average price of $202.09, for a total value of $926,582.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Anthony Hunt sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, September 9th. The shares were sold at an average price of $294.75, for a total value of $7,368,750.00. Following the completion of the sale, the chief executive officer now owns 214,495 shares of the company’s stock, valued at approximately $63,222,401.25. The disclosure for this sale can be found here. Insiders have sold 52,154 shares of company stock valued at $14,144,680 in the last three months. 1.20% of the stock is owned by insiders.
Hedge funds have recently made changes to their positions in the business. RPg Family Wealth Advisory LLC bought a new stake in Repligen in the second quarter valued at approximately $27,000. Creative Financial Designs Inc. ADV raised its holdings in shares of Repligen by 50.0% during the second quarter. Creative Financial Designs Inc. ADV now owns 150 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 50 shares in the last quarter. Itau Unibanco Holding S.A. bought a new position in shares of Repligen during the second quarter valued at approximately $37,000. Rational Advisors LLC bought a new position in shares of Repligen during the second quarter valued at approximately $48,000. Finally, Huntington National Bank raised its holdings in shares of Repligen by 45.5% during the second quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $58,000 after acquiring an additional 91 shares in the last quarter. Hedge funds and other institutional investors own 83.82% of the company’s stock.
About Repligen (NASDAQ:RGEN)
Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs.
Featured Article: What is a Fiduciary?
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.